CDK2 inhibitors may also have clinical utility in subsets of cancers such as high-grade serous ovarian carcinomas, which harbor amplifications in the CCNE1 gene that encodes its partner cyclin E (Etemadmoghadam et al., 2013). This evidence concerns the gene CCNE1 and ovarian serous carcinoma.